Interferon α in the treatment of chronic myelogenous leukemia

Archivum Immunologiae et Therapiae Experimentalis

Volumn 46, Issue 6, 1998, Pages 347-353

  Robak, Tadeusz ^a  

^a University Medical School   (Poland)

Author keywords

Chronic myelogenous leukemia; Interferon ; Mechanism of action; Randomized trials; Treatment

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; PHILADELPHIA 1 CHROMOSOME; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0032443518     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. ALLAN N. C., RICHARDS S. M. and SHEPHERD P. C. A. (1995): U.K. Medical Research Council randomized, multicentre trial of interferon-α N1 for chronic myleoid leukemia: improved survival irrespective of cytogenetic response. Lancet, 345, 1392-1397.
2. Benelux CML Study Group (1996): Low dose interferon alpha-2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia. Bone Marrow Transplant., 17(suppl. 3), 519-520.
3. CLARKSON B. D., STRIFE A., WISNIEWSKI D., LAMBEK C. and CARPINO N. (1997): New understanding of the pathogenesis of CML: a prototype of early neoplasia. Leukemia, 11, 1404-1428.
4. DARNELL J. E. JR., KERR I. M. and STARK G. R. (1994): Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264, 1415-1421.
5. DOWDING C., GUO A. P., MAISIN C., GORDON M. and GOLDMAN J. (1991): The effects of interferon-α on the proliferation of CML progenitor cells are not related to the precise position of MBCR break point. Br. J. Haematol., 77, 165-171.
6. GOLDMAN J. M. (1997): Treatment of chronic myeloid leukemia: some topical questions. Baillieres Clin. Haematol., 10, 405-421.
7. GOLDMAN J. M. (1997): Optimizing treatment for chronic myleoid leukemia. N. Engl. J. Med., 337, 270-272.
8. GORDON M. Y. and GOLDMAN J. M. (1996): Cellular and molecular mechanisms in chronic myleoid leukemia: biology and treatment. Br. J. Haematol., 95, 10-20.
9. GRANDER D., SANGFELT O. and ERICKSON S. (1997): How does interferon exert its cell growth inhibitory effect. Eur. J. Haematol., 59, 129-135.
10. GUILHOT F., CHASTANG C., MICHALLET M., GUERCI A., HAROUSSEAN J. L., MALOISEL F., BOUABDALLAH R., GUYOTAT D., CHERON N., NICOLINI F., ABGRALL J. F. and TAUSER J. (1997): Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N. Engl. J. Med., 337, 223-229.
11. HARIA M. and BENFIELD P. (1995): Interferon α-2a. A review of its pharmacological properties and therapeutic use in management of viral hepatitis. Drugs, 50, 873-896.
12. HASFORD J., BACCARAMI M., MEHLMANN R., AUSARI H., TURA S. and ZUFFA E. (1996): Interferon-α and hydroxyurea in early chronic myleoid leukemia. A comparative analysis of the Italian and German chronic myleoid leukemia trials with interferon-α. Blood, 87, 5384-5391.
13. HEHLMANN R. (1998): A chance for cure for every patient with chronic myleoid leukemia? N. Engl. J. Med., 338, 980-982.
14. HEHLMANN R., HEIMPEL H., HASFORD J., KOLB H. J., PRALLE H., HOSSFELD D. K. and the German CML Study Group (1994): Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myeloid leukemia. Blood, 84, 4064-4077.
15. HEHLMANN R., HEIMPEL H., HASFORD J., KOLB H. J., PRALLE H., HOSSFELD D. K. and the German CML Study Group (1993): Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia (CML), prolongation of survival by hydroxyurea. Blood, 82, 398-407.
16. HEHLMANN R., WILLER A., HEIMPEL H., HASFORD J., KOLB H. J., PRALLE H., HOSSFELD D. K., QUEIBER W., LOFFLER H., HOCHHAUS A., TOBLER A., LENGFELDER E., BERGER U. and LEIB-MÖSCH C. (1997): Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. Leukemia, 11 (suppl), 506-511.
17. HOICHAUS A., LIN F., REITER A., SKLADNY H., MASON P. J., VAN RHENE F., SHEPARD PCA, ALLAN N.C., HEHLMANN R., GOLDMAN J. M. and CROSS C. P. (1996): Quantification of residual disease in chronic myelogenous leukemia on interferon-α therapy by competitive polymerase chain reaction. Blood, 87, 1549-1555.
18. INGLOT A. D. and BLACH-ULSZEWSKA Z. (1991): Interferony. In KAWIAK J., OSUCHOWSKA Z. and JAKOBISIAK M. (eds.): Ultrastruktura i funkcja komórki. PWN, Warszawa, 5, 40-79.
19. Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994): Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myleoid leukemia. N. Engl. J. Med., 330, 820-825.
20. JEHN U., POSTSCHER Ch. and HEINEMANN V. (1995): Successful treatment of accelerated and blastic phase of chronic myleoid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach. Leuk. Lymphoma, 19, 153-157.
21. KANTARJIAN H. M., GIELES F. J., O'BRIEN S. M. and TALPAZ M. (1998): Clinical course and therapy of chronic myelogenous leukemia with interferon alpha and chemotherapy. Hematol. Oncol. Clin. North Am., 12, 31-80.
22. KANTARJIAN H., SMITH T., O'BRIAN S., BERAN M., PIERCE S. and TALPAZ M. (1995): Prolonged survival in chronic myelogenous leukemia following cytogenetic response to alpha interferon therapy. Ann. Intern. Med., 122, 254-261.
23. KORYCKA A. and ROBAK T. (1996): Interaction of 2-chlorodeoxyadenosine in combination either with interferons or recombinant human tumor necrosis factor α on myleoid progenitor cells in vitro. Arch. Immunol. Ther. Exp., 44, 259-264.
24. MANDELLI F., ARCESE W. and AUVISATI G. A. (1994): The interferons in haematological malignancies. Baillieres Clin. Haematol., 7, 91-113.
25. MELO J. U., BOSE S., GÓRA-TYBOR J., DEININGER M. and GOLDMAN J. M. (1997): Detection of leukemia-associated fusion genes in leukocytes from normal people and hematopoietic cell lines using an improved RT/PCR assay. Blood, 90 (suppl 1), 501a (abstr. 2233).
26. NIEDERLE N., KLOKE O., WANDL U. B., BECHER R., MORITZ T. and OPALKA B. (1993): Long-term treatment of chronic myleogenous leukemia with different interferons: results from three studies. Leuk. Lymphoma 9, 111-119.
27. OHNISHI K., OHNO R., TOMONAGA M., KAMADA N., ONOZAWA K., KURAMOTO A., DOHY H., MIZOGUCHI H., MIYAVAKI S., TOUBAKI K., MIURA Y., OMINE M., KOBAYASKI T. and the Kouseisho Leukemia Study Group (1995): A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood, 86, 906-916.
28. RANSOHOFF R. M. (1998): Cellular responses to interferons and other cytokines; the JAK-STAT paradigm. N. Engl. J. Med., 338, 616-618.
29. RICHARDS S. M. (1997): Interferon-α results from randomized trials. Baillieres Clin. Haematol., 10, 307-318.
30. ROBAK T. (1995): Biologia i farmakologia cytokin. Wydawnictwo Naukowe PWN, Warszawa - Łódź, 23-45.
31. ROBAK T. (1996): Cytokines in the treatment of hematological disordes: recent progress and perspectives. Arch. Immunol. Ther. Exp., 44, 5-9.
32. ROBAK T. and KORYCKA A. (1996): The comparison of 2-chlorodeoxyadenosine (2-CdA) in combination with interferon-α (IFN-α) or interferon-γ (IFN-γ) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts (CFU-L) in cultures in vitro. Leuk. Lymphoma, 21, 161-168.
33. ROBAK T., KORYCKA A. and GORA-TYBOR J. (1994): The interaction of 2-chlorodeoxyadenosine (2-CdA) and interferon α (IFN-α) on normal and myeloid leukemia hematopoiesis in vitro. Leuk. Res., 18, 275-281.
34. SACCHI S., KANTARJIAN H. M., O'BRIAN S., BERAN M., KOLLER C., PIERCE S., KORUBLAN S., ESTEY E., KEATING M. J. and TALPAZ M. (1997): Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Leukemia, 1610-1616.
35. SANGFELT O., ERICKSON S., EINHORN S., CASTRO J., HEIDEN T. and GRANDER D. (1997): Induction of apoptosis and inhibition of cell growth are independent responses of cells to interferon-α in hematopoietic cell lines. Cell Growth Differ., 8, 343-352.
36. Schofield J. R., ROBINSON W. A., MURPHY J. A. and ROVIRA D. K. (1994): Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myleoid leukemia. Ann. Intern. Med., 121, 736-744.
37. TALPAZ M., KANTARJIAN H. M., KURZROCK R. TRUJILLO J. and GUTTERMAN J. (1991):. Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann. Intern. Med., 114, 532-538.
38. TALPAZ M., MC CREDIE K. B., MAVLIGIT G. M. and GUTTERMAN J. U. (1983): Leukocyte interferon-induced myleoid cytoreduction in chronic myelogenous leukemia. Blood, 62, 689-692.
39. TURA S. and BACCARANI M. (1995): α-Interferon in the treatment of chronic myleoid leukemia. Blood, 85, 2999-3000.
40. VALAZQUEZ L., FELLOUS M., STARK G. R. and PELLEGRINI S. (1992): A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell, 70, 313-322.
41. WELANDER C. E. (1987): Overview of preclinical studies of interferon alpha-2b combination with cytotoxic drugs. Invest. New Drugs, 5 (suppl.), 45-54.
42. WELZLER M., KANTARJIAN H., KURZROCK R. and TALPAZ M. (1995): Interferon-α therapy for chronic myelogenous leukemia. Ann. Intern. Med., 99, 402-411.